MX374827B - Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer. - Google Patents
Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer.Info
- Publication number
- MX374827B MX374827B MX2014012233A MX2014012233A MX374827B MX 374827 B MX374827 B MX 374827B MX 2014012233 A MX2014012233 A MX 2014012233A MX 2014012233 A MX2014012233 A MX 2014012233A MX 374827 B MX374827 B MX 374827B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- gene
- vitro method
- subject suffering
- prognosis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011338 personalized therapy Methods 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 230000003321 amplification Effects 0.000 abstract 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 3
- 206010027476 Metastases Diseases 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 102100039189 Transcription factor Maf Human genes 0.000 abstract 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621949P | 2012-04-09 | 2012-04-09 | |
| EP12382139.9A EP2650682A1 (en) | 2012-04-09 | 2012-04-09 | Method for the prognosis and treatment of cancer metastasis |
| US201261724807P | 2012-11-09 | 2012-11-09 | |
| US201261732175P | 2012-11-30 | 2012-11-30 | |
| PCT/IB2013/001204 WO2013153458A2 (en) | 2012-04-09 | 2013-03-15 | Method for the prognosis and treatment of cancer metastasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014012233A MX2014012233A (es) | 2015-06-17 |
| MX374827B true MX374827B (es) | 2025-03-06 |
Family
ID=45929479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014012233A MX374827B (es) | 2012-04-09 | 2013-03-15 | Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9702878B2 (enExample) |
| EP (3) | EP2650682A1 (enExample) |
| JP (4) | JP6381519B2 (enExample) |
| KR (2) | KR102252332B1 (enExample) |
| CN (1) | CN104797935B (enExample) |
| AU (1) | AU2013246618B9 (enExample) |
| BR (1) | BR112014025269B1 (enExample) |
| CA (1) | CA2891609C (enExample) |
| DK (2) | DK2836837T3 (enExample) |
| ES (2) | ES2798107T3 (enExample) |
| FI (1) | FI3825692T3 (enExample) |
| MX (1) | MX374827B (enExample) |
| WO (1) | WO2013153458A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| DK2906718T3 (da) | 2012-10-12 | 2019-07-01 | Inbiomotion Sl | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf |
| AU2014229505B2 (en) * | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) * | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| JP6550045B2 (ja) * | 2013-10-09 | 2019-07-24 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 |
| JP2017538412A (ja) * | 2014-12-11 | 2017-12-28 | インバイオモーション エセ．エレ． | ヒトｃ−ｍａｆに対する結合メンバー |
| WO2016145294A1 (en) * | 2015-03-12 | 2016-09-15 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
| ES2883249T3 (es) * | 2015-03-17 | 2021-12-07 | Mayo Found Medical Education & Res | Métodos y materiales para evaluar y tratar el cáncer |
| WO2017044715A1 (en) * | 2015-09-09 | 2017-03-16 | Somalogic, Inc. | Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles |
| CA3021445A1 (en) * | 2016-04-19 | 2017-10-26 | Exelixis, Inc. | Triple negative breast cancer treatment method |
| CN117230193A (zh) * | 2016-05-25 | 2023-12-15 | 生物运动有限公司 | 基于c-maf状态的乳腺癌治疗性治疗 |
| CN105907886A (zh) * | 2016-07-07 | 2016-08-31 | 蔡维泺 | miR-124在乳腺癌骨转移疾病中的应用 |
| JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 |
| CN108796071A (zh) * | 2017-04-26 | 2018-11-13 | 中国科学院上海生命科学研究院 | 转移性乳腺癌标记物及其在诊断和治疗中的应用 |
| EP3713581A1 (en) * | 2017-11-22 | 2020-09-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf |
| KR102664243B1 (ko) * | 2018-01-19 | 2024-05-08 | 데루타-후라이 화마 가부시키가이샤 | 암 환자의 치료에 유용한 오줌의 알칼리제 |
| KR102224910B1 (ko) * | 2018-06-26 | 2021-03-05 | 재단법인 의약바이오컨버젼스연구단 | Rna 은 제자리 혼성화 방법을 통한 aimp2-dx2 신호 자동화 검출 방법 |
| CN110656171B (zh) * | 2018-06-28 | 2023-05-05 | 润安医学科技(苏州)有限公司 | 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途 |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| US12139764B2 (en) | 2018-11-14 | 2024-11-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for characterizing and treating breast cancer |
| WO2021062261A1 (en) * | 2019-09-25 | 2021-04-01 | The Trustees Of Columbia University In The City Of New York | Prognostic markers of metastatic cancer |
| CN112662763A (zh) * | 2020-03-10 | 2021-04-16 | 博尔诚（北京）科技有限公司 | 一种检测常见两性癌症的探针组合物 |
| CN112662764A (zh) * | 2020-03-17 | 2021-04-16 | 博尔诚（北京）科技有限公司 | 一种检测11种癌症的探针组合物 |
| JP7607330B2 (ja) * | 2021-04-30 | 2024-12-27 | 国立大学法人金沢大学 | 骨腫瘍の予後診断方法又は予後診断補助方法 |
| WO2022271702A1 (en) * | 2021-06-21 | 2022-12-29 | Palvella Therapeutics, Inc. | Methods and compositions for treating gorlin syndrome |
| IT202200001817A1 (it) | 2022-02-02 | 2023-08-02 | Aizoon S R L | Procedimento per la prognosi di una malattia in seguito ad un trattamento terapeutico, relativo sistema e prodotto informatico |
| WO2023158783A2 (en) * | 2022-02-18 | 2023-08-24 | Vuja De Sciences, Inc. | Methods, compositions, and combinations for preventing or treating cancer recurrence |
| IT202200005861A1 (it) | 2022-03-24 | 2023-09-24 | Aizoon S R L | Procedimento per stimare una variabile di interesse associata ad una data malattia in funzione di una pluralità di diversi dati omici, relativo dispositivo e prodotto informatico |
| CA3207405A1 (en) | 2022-07-25 | 2024-01-25 | Aizoon S.r.l. | Method for providing a clinical decision support, corresponding system for providing a clinical decision support, and computer program product |
| CN115919464B (zh) * | 2023-03-02 | 2023-06-23 | 四川爱麓智能科技有限公司 | 肿瘤定位方法、系统、装置及肿瘤发展预测方法 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
| CN119662833B (zh) * | 2025-01-22 | 2025-08-15 | 中山大学孙逸仙纪念医院 | 基于肿瘤小泡中circCCDC50的Luminal型乳腺癌骨转移标记物、预测诊断试剂盒 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0217822B1 (en) | 1985-02-13 | 1993-05-12 | Scios Nova Inc. | Human metallothionein-ii promoter in mammalian expression system |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| DE4013632A1 (de) | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| CA2251466A1 (en) | 1996-04-05 | 1997-10-16 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| WO1998028424A2 (en) | 1996-12-23 | 1998-07-02 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| HRP20010738B1 (en) | 1999-03-15 | 2005-02-28 | Axys Pharmaceuticals | N-cyanomethyl amides as protease inhibitors |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| DE60132975T2 (de) | 2000-01-06 | 2009-02-26 | Merck Frosst Canada Inc., Kirkland | Neue substanzen und verbindungen als protease-inhibitoren |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| ES2706902T3 (es) | 2001-06-26 | 2019-04-01 | Amgen Inc | Anticuerpos para OPGL |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| JP4579246B2 (ja) | 2003-09-24 | 2010-11-10 | オンコセラピー・サイエンス株式会社 | 乳癌を診断する方法 |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1730308A4 (en) * | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| EP3211086B1 (en) | 2005-09-20 | 2021-06-09 | Menarini Silicon Biosystems S.p.A. | Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes |
| EP1931994A2 (en) | 2005-09-26 | 2008-06-18 | Novartis AG | Molecular markers associated with bone metastasis |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US8173825B2 (en) | 2006-12-20 | 2012-05-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Method of making fatty acid ester derivatives |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| WO2008145125A1 (en) | 2007-05-31 | 2008-12-04 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
| NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009049410A1 (en) | 2007-10-18 | 2009-04-23 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| US20110130296A1 (en) | 2008-03-14 | 2011-06-02 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| CN102123708A (zh) | 2008-06-06 | 2011-07-13 | 大学健康网络 | 用于治疗恶性血液疾病的8-羟基喹啉衍生物 |
| ES2338843B1 (es) | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| ES2546410T3 (es) | 2009-08-06 | 2015-09-23 | John Wayne Cancer Institute | Diagnosis de cáncer de mama, y otros tipos de cáncer, de tipo basal primario y metastásico |
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| US20140162887A1 (en) | 2011-02-04 | 2014-06-12 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| AU2012229123B2 (en) | 2011-03-15 | 2017-02-02 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with anthracycline therapy |
| EP2780469A1 (en) | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| DK2906718T3 (da) | 2012-10-12 | 2019-07-01 | Inbiomotion Sl | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf |
| AU2014229505B2 (en) | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| JP6550045B2 (ja) | 2013-10-09 | 2019-07-24 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 |
| JP2017538412A (ja) | 2014-12-11 | 2017-12-28 | インバイオモーション エセ．エレ． | ヒトｃ−ｍａｆに対する結合メンバー |
| CN117230193A (zh) | 2016-05-25 | 2023-12-15 | 生物运动有限公司 | 基于c-maf状态的乳腺癌治疗性治疗 |
| EP3713581A1 (en) | 2017-11-22 | 2020-09-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf |
-
2012
- 2012-04-09 EP EP12382139.9A patent/EP2650682A1/en not_active Withdrawn
-
2013
- 2013-03-15 ES ES13731875T patent/ES2798107T3/es active Active
- 2013-03-15 EP EP13731875.4A patent/EP2836837B1/en active Active
- 2013-03-15 KR KR1020147031148A patent/KR102252332B1/ko active Active
- 2013-03-15 DK DK13731875.4T patent/DK2836837T3/da active
- 2013-03-15 ES ES20170652T patent/ES2995194T3/es active Active
- 2013-03-15 FI FIEP20170652.0T patent/FI3825692T3/fi active
- 2013-03-15 CA CA2891609A patent/CA2891609C/en active Active
- 2013-03-15 KR KR1020217014022A patent/KR102442275B1/ko active Active
- 2013-03-15 WO PCT/IB2013/001204 patent/WO2013153458A2/en not_active Ceased
- 2013-03-15 US US14/391,085 patent/US9702878B2/en active Active
- 2013-03-15 CN CN201380027292.1A patent/CN104797935B/zh active Active
- 2013-03-15 AU AU2013246618A patent/AU2013246618B9/en active Active
- 2013-03-15 DK DK20170652.0T patent/DK3825692T3/da active
- 2013-03-15 JP JP2015505034A patent/JP6381519B2/ja active Active
- 2013-03-15 EP EP20170652.0A patent/EP3825692B1/en active Active
- 2013-03-15 MX MX2014012233A patent/MX374827B/es active IP Right Grant
- 2013-03-15 BR BR112014025269-6A patent/BR112014025269B1/pt active IP Right Grant
-
2017
- 2017-05-30 US US15/608,036 patent/US10866241B2/en active Active
-
2018
- 2018-03-27 JP JP2018059907A patent/JP6781184B2/ja active Active
-
2020
- 2020-10-15 JP JP2020174192A patent/JP2021007408A/ja not_active Withdrawn
- 2020-12-01 US US17/108,390 patent/US12196758B2/en active Active
-
2022
- 2022-06-21 JP JP2022099476A patent/JP2022125079A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374827B (es) | Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer. | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| GB2531881A (en) | Method of isolating circulating tumor cells | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| MX2019007814A (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| MX340453B (es) | Biomarcadores para cancer de pulmon. | |
| MX375138B (es) | Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal. | |
| AR105618A1 (es) | Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer | |
| MX2014001246A (es) | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. | |
| NZ720626A (en) | Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers | |
| ES2618353T3 (es) | Clasificación de tumores y pronóstico del cáncer de mama | |
| MX2013014153A (es) | Biomarcadores paa terapia de inhibidor de hedgehog. | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| IN2012DN04944A (enExample) | ||
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| MX2019011017A (es) | Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii. | |
| MX2019013953A (es) | Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia. | |
| PH12014502410A1 (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression | |
| IN2015DN01646A (enExample) | ||
| GB201016690D0 (en) | Method of detecting cancer | |
| MX2020000293A (es) | Microrna-455-3p como un marcador bioperiferico para la enfermedad de alzheimer. | |
| MX2017002453A (es) | Neprilisina como marcador pronostico de insuficiencia cardiaca. | |
| PL413907A1 (pl) | Sposób wykrywania genetycznie uwarunkowanej zwiększonej predyspozycji do raka jelita grubego | |
| CL2011001209A1 (es) | Metodo en vitro para determinar pronostico de un cancer papilar de tiroides que comprende cuantificar, en una muestra, la expresion del receptor de quimiokina ccr3 y donde su sobreexpresion respecto de un valor de referencia indica que el tumor tiene altas probabilidades de invadir la capsula y generar metastasis. | |
| PL415642A1 (pl) | Stężenie żelaza we krwi i zmiany w obrębie genu HFE jako czynniki ryzyka raków u mężczyzn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |